Newsletters
View the news of 2011 Fall and Winter and other exciting developments at the ADRC!
A New Clinical Trial of a Red Wine Derivative By Judith Neugroschl, M.D. The Mount Sinai ADRC is excited to announce our participation in a new nationwide study examining the effect of resveratrol in patients with mild to moderate Alzheimer’s disease (AD). What makes this trial unique is that in addition to the traditional paper [...]
Please see our latest edition of our newsletter!
http://www.delay-ad.org/2011/06/02/new-ways-to-diagnose-alzheimer%E2%80%99s-disease/adrc-newsletter-fall-2010/
Mouse Study Shows Effect of Blood Pressure Drug on Alzheimer’s Disease
From 11/15/2010 NIA News Release, with Response by Sam Gandy, M.D. A drug used decades ago to treat high blood pressure has been shown to improve learning and memory in mouse models of Alzheimer’s disease, according to a new study by researchers at the National Institute on Aging (NIA), part of the National Institutes of [...]
Ask the Expert: Do any of the prevention strategies for Alzheimer’s have any merit? I heard that there was a recent NIH panel that said that none of them were useful!
Ask the expert: Judith Neugroschl, M.D. The NIH recently sponsored a panel made up of 15 specialists in a variety of fields of medicine and public health, along with 20 expert presenters, in order to assess the current research on Alzheimer’s disease prevention. They came up with a consensus statement with a couple of major [...]
Gene Linked to Increased Risk of Alzheimer’s Disease
Adapted by Steven Hoover from the 9/24/2010 EmaxHealth posting by Deborah Mitchell Researchers are one step closer to discovering the genetic precursors to lateonset Alzheimer’s disease, the most common type of the disease. Investigators from four institutions, including Dr. Joseph Buxbaum of Mount Sinai Medical Center, collaborated to discover the role of variations in a [...]
New Ways to Diagnose Alzheimer’s Disease
Over the past 25 years there have been few changes in the diagnosis of Alzheimer disease (AD) even though our knowledge of the disease and its progression has grown. For example, the current criteria have age cutoffs (between 40 and 90 years of age), but we know now that many people living into their 90’s [...]
Gene Associated with Type 2 Diabetes Is Low in People with Alzheimer’s Disease
From October 12, 2010 MSSM Press Release Mount Sinai School of Medicine researchers have found that a gene associated with the onset of Type 2 diabetes also is found at lower-than-normal levels in people with Alzheimer’s disease. The research, led by Giulio Maria Pasinetti, MD, PhD, The Saunder Family Professor in Neurology, and Professor of [...]
Alzheimer’s Memory Problems May Originate with Oligomers, Not Amyloid Plaques
From “Mount Sinai Press Release,” dated 4/27/10 A recent study published in April 2010 in the Annals of Neurology suggests that the prevailing theory of sticky amyloid plaques as the cause to Alzheimer’s disease may in fact be wrong. New research by Sam Gandy, M.D., Ph.D., the Associate Director of the Mount Sinai Alzheimer’s Disease [...]
Could head injury be a risk factor for Alzheimer’s disease?
The first evidence of a link between history of head injury and risk for developing Alzheimer’s disease (AD) was a case report of AD pathology in the brain of a 38 year-old man who had suf- fered a single episode of a head injury 16 years earlier. This finding lead to the idea that head [...]
Ask the Expert: What is the history behind vaccinations for Alzheimer’s disease, and how promising are they for the treatment of AD?
A potential “Alzheimer’s vaccine” has long been an interest for researchers and a hope for patients and families. The primary target for most vaccines to date has been the amyloid plaque which is found in the brains of patients with AD, and is thought by many to be the cause of the disease. The idea of using the body’s own immunity to combat amyloid buildup has great appeal…